Mesenchymal stromal cells: Getting ready for clinical primetime.

Area of Science:

• Cellular biology
• Immunology
• Regenerative medicine

Background:

• Mesenchymal stromal cells (MSCs) are multipotent stem cells with immune regulatory properties.
• Their potential for allogeneic transplantation is due to low MHC expression and immune evasion capabilities.
• MSCs are being investigated for inflammatory and autoimmune conditions, with a strong safety record established over 20 years of clinical trials.

Purpose of the Study:

• To review the proposed mechanisms of action for MSCs.
• To discuss the clinical application of MSCs, particularly for steroid-refractory acute graft-versus-host disease (SR-aGVHD).
• To explore potential strategies for enhancing MSC efficacy.

Main Methods:

• Review of existing literature on MSC mechanisms, clinical trials, and manufacturing.
• Focus on SR-aGVHD as a key clinical indication.
• Analysis of factors influencing MSC efficacy in therapeutic settings.

Main Results:

• MSCs possess significant immune-modulatory functions, making them attractive for cell therapy.
• While demonstrating an excellent safety profile, consistent efficacy data is pending for widespread regulatory approval.
• Recent Phase III trial data for pediatric SR-aGVHD shows encouraging results.

Conclusions:

• MSCs hold therapeutic potential for various immune-related diseases, especially SR-aGVHD.
• Further research is needed to optimize patient selection, trial design, and manufacturing processes.
• Enhancing MSC efficacy through novel modalities is crucial for broader clinical adoption.